Sales and profits rebounded strongly in Q1 FY2026, with net income turning positive and all major segments except ICT & Mobility Solutions and Sumitomo Pharma showing improved core operating income. Full-year guidance remains unchanged, with a stable dividend outlook.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.